Psoriasis Treatment Market to Surpass US$ 87.6 Bn by 2035 Amid Surge in Biologic Therapies and Regulatory Approvals

The global psoriasis treatment market was valued at US$ 35.0 Bn in 2024 and is projected to grow at a CAGR of 9.5% between 2025 and 2035 to reach over US$ 87.6 Bn by the end of 2035, according to a report published by Transparency Market Research Inc.

The market is experiencing robust expansion, primarily fueled by a rising prevalence of psoriasis, increased access to healthcare, and significant progress in biologic therapies. Pharmaceutical companies are investing in next-generation interleukin inhibitors and digital monitoring solutions, paving the way for more precise and accessible treatments.

Get Sample PDF Brochure from here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17960

Analysts' Viewpoint

The growing global burden of psoriasis-currently affecting over 125 million people worldwide-is driving demand for effective, long-term treatment options. Biologics, especially IL-17 and IL-23 inhibitors, are becoming the cornerstone for moderate to severe cases due to their high efficacy, targeted mechanisms, and favorable safety profiles.

Despite challenges such as high treatment costs, especially in low-income regions, emerging biosimilars, digital therapeutics, and AI-powered diagnostic support systems are improving affordability and accessibility. These trends are expected to redefine the landscape of psoriasis care over the next decade.

Key Market Drivers

Rising Prevalence of Psoriasis
According to NCBI (2022), the global prevalence of psoriasis ranges from 0.33% to 0.6%, impacting approximately 125 million people. The increasing incidence of psoriatic arthritis (PsA)-present in up to 40% of psoriasis patients-further elevates the demand for treatment.

Increasing Regulatory Approvals
Recent FDA approvals are expanding treatment choices:

May 2025 - Arcutis Biotherapeutics received FDA approval for ZORYVE topical foam 0.3% to treat plaque psoriasis in patients aged 12+.
August 2024 - Amgen launched Otezla for pediatric patients (ages 6+) with moderate to severe plaque psoriasis.
September 2022 - Bristol Myers Squibb gained FDA approval for Sotyktu (deucravacitinib), a first-in-class TYK2 inhibitor.
These approvals enhance patient outcomes while encouraging further innovation in the segment.

Segment Insights

By Drug Type: Biologics Lead the Market

Biologics, particularly interleukin inhibitors (IL-17 & IL-23), dominate the psoriasis treatment market.
These treatments offer fewer systemic side effects, higher patient adherence, and significant skin clearance rates in moderate to severe cases.

Other Drug Classes:

Small Molecule Drugs - PDE4 inhibitors, TYK2 inhibitors (e.g., deucravacitinib)
Topical Agents - Corticosteroids, Vitamin D analogues, AHR agonists

By Type of Psoriasis:

Plaque Psoriasis remains the most common and well-studied subtype.
Others include:
Guttate Psoriasis
Inverse Psoriasis
Pustular Psoriasis
Erythrodermic Psoriasis
Nail Psoriasis

Regional Outlook

North America Maintains Market Leadership

North America, particularly the United States, remains the largest market, backed by:

A high psoriasis prevalence
Advanced biologic approvals
Supportive reimbursement infrastructure
Strong pharma R&D ecosystem

Initiatives such as Psoriasis Awareness Month and expanding insurance coverage are further contributing to increased diagnosis and treatment rates.

Asia Pacific Poised for Rapid Growth

Asia Pacific offers substantial growth opportunities, driven by:

Improved healthcare infrastructure
Growing awareness of chronic skin diseases
Rising biologic adoption in countries like Japan, South Korea, and China

Key Market Players

Bristol-Myers Squibb Company
AbbVie Inc
Amgen Inc
AstraZeneca
Eli Lilly and Company
Johnson & Johnson Services, Inc.
LEO Pharma A/S
Merck & Co., Inc.,
Novartis AG
Boehringer Ingelheim Pharmaceuticals, Inc.
Arcutis Biotherapeutics, Inc
Dermavant Sciences, Inc.
TIEFENBACHER GROUP
UCB S.A.
Bausch Health
Sun Pharmaceutical Industries Limited
Akeso Biopharma Co., Ltd.
Other Prominent Players

Recent Industry Developments

Aug 2024: Amgen launched Otezla for pediatric psoriasis patients ≥6 years, becoming the first FDA-approved oral therapy for this group.
May 2025: ZORYVE topical foam (roflumilast) approved for scalp and body plaque psoriasis (ages 12+).
Sept 2022: FDA approved Sotyktu (deucravacitinib) by BMS-a breakthrough oral TYK2 inhibitor.

Buy this Premium Research Report:

https://www.transparencymarketresearch.com/checkout.php?rep_id=17960<ype=S

Explore Latest Research Reports by Transparency Market Research:

Ophthalmic Drugs Market- https://www.transparencymarketresearch.com/ophthalmic-drugs-market.html

Pain Management Therapeutics Market- https://www.transparencymarketresearch.com/pain-management-therapeutics.html

Addiction Treatment Market- https://www.transparencymarketresearch.com/addiction-treatment-market.html

Biologics Market- https://www.transparencymarketresearch.com/global-biologics-market.html

Oral Thin Films Market- https://www.transparencymarketresearch.com/oral-thin-films-market.html

Contact Us:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

This release was published on openPR.